(CIDRAP News) In light of vaccine production problems that delayed the delivery of the pandemic H1N1 vaccine, a report by President Barack Obama's science advisers released today said targeted investments in five specific areas could trim the time needed to quickly produce enough to protect the nation by weeks or months.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) In advance of the expected pandemic H1N1 vaccination campaign this fall, the US Department of Health and Human Services (HHS) yesterday invited the media to join federal officials in a tabletop exercise to prepare for some possible communications challenges.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) In an update on the nation's pandemic preparedness efforts, the US Department of Health and Human Services (HHS) yesterday said it had stockpiled enough H5N1 avian influenza vaccine to protect about 6 million people and that federal and state supplies contain enough antiviral medication to treat more than 48 million.
(CIDRAP News) – A US Food and Drug Administration (FDA) panel today recommended that the agency approve the nation's first H5N1 influenza vaccine, despite new evidence that the vaccine is less protective than reported in a clinical trial last year.